---
title: "TuHURA Biosciences, Inc. (HURA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HURA.US.md"
symbol: "HURA.US"
name: "TuHURA Biosciences, Inc."
industry: "Biotechnology"
datetime: "2026-06-10T04:56:46.371Z"
locales:
  - [en](https://longbridge.com/en/quote/HURA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HURA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HURA.US.md)
---

# TuHURA Biosciences, Inc. (HURA.US)

## Company Overview

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company’s lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.tuhurabio.com](https://www.tuhurabio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.16 | 358 | - | - | - |
| PB | 5.61 | 344 | 8.71 | 6.53 | 4.54 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-27T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 40% |
| Overweight | 2 | 40% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.82 |
| Highest Target | 15.00 |
| Lowest Target | 9.25 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HURA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HURA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HURA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HURA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**